October often marks an important turning point for life sciences organizations.
For teams working toward a year-end regulatory submission, manufacturing milestone, or upcoming product launch, the remaining calendar can feel especially short. Teams must assemble final documentation, satisfy quality requirements, validate manufacturing processes, and align resources for the work still ahead.
At the same time, leaders are making decisions about 2027 priorities, budgets, and workforce capacity.
A launch can appear on schedule while a handful of unresolved dependencies put readiness at risk. Regulatory may be waiting on final validation documentation. Quality may be managing an unexpected deviation. Manufacturing may be preparing for scale-up while critical technical resources are already committed elsewhere.
These challenges become harder to resolve as submission and launch dates approach.
October is an opportunity for life sciences leaders to confirm that quality, regulatory, manufacturing, and supporting teams are working from the same plan. It’s also the time to address potential life sciences staffing gaps, particularly when an upcoming milestone requires specialized expertise that cannot be secured or onboarded quickly.
The Final Stretch Before Launch Puts Execution to the Test
Product development involves years of coordinated work, but the period leading up to submission and commercialization introduces a different kind of pressure.
Timelines narrow. Documentation requirements intensify. Cross-functional dependencies become more visible. A delay within one department can affect the work of several others.
Recent industry research reinforces the importance of disciplined execution.
Deloitte’s June 2026 Midyear Life Sciences Outlook found that life sciences executives were increasingly focused on productivity, commercial performance, investment discipline, and operational resilience. Its analysis of first-quarter earnings calls also identified launch execution and pipeline progress among the issues attracting investor attention.
For organizations approaching a critical milestone, disciplined execution requires clear ownership of deliverables, visibility into cross-functional dependencies, and a realistic understanding of the resources available to complete the work.
The importance of cross-functional execution across the product lifecycle becomes particularly evident as products move toward submission and commercialization. Each participating function must understand its responsibilities and how its work affects the broader program timeline.
Four Areas That Require Alignment Before a Critical Launch Milestone
While requirements differ across pharmaceutical, biotechnology, and medical device organizations, four interconnected workstreams deserve particular attention during launch and submission planning.
1. Regulatory Affairs: Is the Submission Package Truly Ready?
Regulatory teams often become the focal point as submission deadlines approach. Yet much of the information required to complete a submission originates elsewhere in the organization.
Clinical data, manufacturing documentation, validation results, labeling, and quality records may all contribute to the final package, depending on the product and applicable regulatory pathway.
This makes early coordination essential.
Recent FDA publications reinforce the importance of product-specific submission planning. In May 2026, the agency released final guidance on Chemistry, Manufacturing, and Controls (CMC) flexibilities for certain cell and gene therapy products being developed for biologics and license applications. In September, the agency also released draft guidance covering electronic Premarket Approval (PMA) submission templates for medical devices and certain supplements. The September guidance remains a draft and is not yet intended for implementation.
For regulatory affairs leaders, preparation requires sufficient time and expertise to coordinate contributors, review documentation, identify outstanding gaps, and resolve issues before they affect the target submission date.
2. Quality & Compliance: Is the Team Ready for the Milestone?
Quality teams play a central role in determining whether a product, process, or facility meets applicable requirements.
As a milestone approaches, unresolved deviations, incomplete validation records, open corrective and preventive actions (CAPAs), or outstanding supplier-quality issues can become significant obstacles.
For QA/QC leaders, readiness planning should include a realistic assessment of:
- Open deviations, investigations, and CAPAs
- Validation documentation and outstanding testing
- Data integrity and documentation completeness
- Supplier qualifications and quality agreements
- Inspection and audit preparedness
- Quality review and release responsibilities
The workload can become substantial when several activities converge on the same timeline.
Organizations may need additional quality systems expertise, validation specialists, QA reviewers, or experienced compliance professionals to address temporary increases in demand while maintaining appropriate oversight.
3. Manufacturing: Is the Process Ready to Deliver Reliably?
Manufacturing readiness requires confidence in the processes, people, materials, and documentation needed to support production.
Depending on the product and stage of development, teams may need to complete technology transfer, process validation, equipment qualification, material planning, analytical testing, and production documentation before commercial supply can begin.
For pharmaceutical and biotechnology organizations, this often means close coordination among manufacturing, quality, MSAT, supply chain, and regulatory affairs.
Medical device manufacturers face their own production-readiness requirements, including process validation where applicable, supplier controls, quality-system documentation, and the transition from development into commercial manufacturing.
A launch timeline can become vulnerable when technical expertise is spread across too many initiatives or manufacturing support enters the process too late.
Leaders should evaluate whether the team has adequate capacity to complete outstanding work, manage unexpected findings, and support the transition to routine operations.
4. Clinical & Commercial Operations: Are the Handoffs Clear?
Clinical and commercial teams have important responsibilities at different points in the product lifecycle, but their work must remain connected to the overall launch plan.
For pharmaceutical and biotechnology programs, outstanding clinical data, medical writing, evidence requirements, and regulatory questions can influence submission readiness.
In July 2026, IQVIA identified several preventable clinical design pitfalls, including misaligned endpoints, unrealistic operational assumptions, and gaps in regulatory alignment. While these challenges often originate earlier in development, they reinforce the importance of continued coordination among clinical, regulatory, and operational teams as programs advance.
Commercial preparation adds coordination around product information, supply availability, market access, training, and launch planning, subject to the necessary regulatory authorizations.
For medical device organizations, transitions may involve design and development records, manufacturing transfer, customer training, distribution readiness, and applicable postmarket responsibilities.
The individuals coordinating these activities need a clear understanding of what must happen, when it must happen, and who owns each dependency.
A launch timeline is only as reliable as the handoffs supporting it.
Closing the Expertise Gaps Before They Affect the Timeline
Even organizations with experienced internal teams can encounter temporary capacity constraints as submission and launch dates approach.
A regulatory submission may require concentrated support from professionals with experience in a particular therapeutic area or application type. Manufacturing scale-up may call for validation and technical operations expertise the organization does not need year-round.
Similarly, quality teams may need additional capacity to manage documentation, investigations, audits, or release activities.
Having access to qualified candidates is only part of the equation. Their experience must match the program’s specific demands.
A regulatory professional may have extensive submission experience but limited familiarity with a particular product modality. Similarly, a manufacturing engineer may have worked in regulated production without having led the technology-transfer or validation activities required by the upcoming initiative.
When evaluating life sciences staffing needs, organizations should start with the work that must be completed, the technical and regulatory expertise it requires, and how quickly someone needs to contribute.
For organizations simultaneously advancing clinical programs, access to specialized clinical and research talent may also become part of the readiness discussion.
Matching Workforce Support to the Needs of the Program
Not every capacity gap requires a permanent hire. The appropriate support model depends on the nature of the work, the expertise already available, and the level of accountability required.
There are three ways life sciences organizations can approach these needs.
Advisory & Consulting: When Experience Can Help Reduce Execution Risk
Experienced life sciences advisors can help organizations evaluate readiness, clarify priorities, identify operational gaps, and establish a more effective path toward a critical milestone.
This may be particularly valuable when navigating a complex regulatory initiative, reviewing manufacturing-readiness plans, or strengthening governance across multiple workstreams.
Project-Based Solution Delivery: When a Defined Initiative Requires Ownership
Some activities are better managed as dedicated projects with clear deliverables, timelines, and responsibilities.
Examples may include coordinating a technology-transfer initiative, supporting validation activities, preparing for an inspection, or managing a defined quality-system improvement project.
This approach gives internal teams access to delivery expertise and structured project oversight without requiring every capability to become a permanent internal function.
Talent-Powered Execution: When Specialized Capacity Is the Priority
In other situations, the strategy and project structure are already established. The organization needs additional professionals who can integrate into existing teams and help complete the work.
Contract, contract-to-hire, and direct-hire solutions can support these requirements across regulatory affairs, QA/QC, manufacturing, clinical operations, and other life sciences disciplines.
Whether the need involves pharmaceutical staffing, medical device staffing, or highly specialized regulatory affairs staffing, the priority should remain the same: align the individual’s experience with the realities of the program.
The right engagement model allows organizations to strengthen execution while remaining thoughtful about long-term workforce commitments.
Make Launch Readiness Part of the Workforce Plan
For organizations approaching a year-end submission, preparing for commercialization, or establishing their 2027 development priorities, workforce readiness should be part of the broader launch plan.
The final readiness review should confirm which expertise is needed, who is accountable for outstanding deliverables, and where additional resources may be required through the next milestone and beyond.
Addressing those needs early gives quality, regulatory, manufacturing, and supporting teams more room to resolve issues, manage dependencies, and carry the right expertise into the next phase of the program.
